Xeloda and Muscle function loss - a phase IV clinical study of FDA data

Summary:

Muscle function loss is reported as a side effect among people who take Xeloda (capecitabine), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Herceptin, and have Rectal cancer.

The phase IV clinical study analyzes which people have Muscle function loss when taking Xeloda. It is created by eHealthMe based on reports of 46,293 people who have side effects when taking Xeloda from the FDA, and is updated regularly.

What is Xeloda?

Xeloda has active ingredients of capecitabine. It is often used in colon cancer. eHealthMe is studying from 46,649 Xeloda users. Check the latest studies of Xeloda.

What is Muscle function loss?

Muscle function loss is found to be associated with 1,000 drugs and 1,520 conditions by eHealthMe. Check the latest studies of Muscle function loss.

On Jul, 19, 2026

46,293 people reported to have side effects when taking Xeloda.
Among them, 47 people (0.1%) have Muscle function loss.

Could Xeloda cause Muscle function loss?

Among these 47 people:

How long have people been on Xeloda when they have Muscle function loss? *

What is the gender of people who have Muscle function loss when taking Xeloda? *

female: 82.98 %
male: 17.02 %

What is the age of people who have Muscle function loss when taking Xeloda? *

What are other drugs people take besides Xeloda? *

What are other side effects people have besides Muscle function loss? *

Fatigue (feeling of tiredness): 4 people, 8.51%
Pneumonia: 4 people, 8.51%
Pain: 4 people, 8.51%
Gait Disturbance: 4 people, 8.51%
Diarrhea: 4 people, 8.51%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 4 people, 8.51%
Nail Disorder (disease of nail): 4 people, 8.51%
Metastasis (spreadable cancer to other organ from origin): 3 people, 6.38%
Disease Progression: 3 people, 6.38%
Muscle Rigidity (muscle stiffness): 3 people, 6.38%

What are the existing conditions these people have? *

Rectal Cancer (cancer of rectum): 4 people, 8.51%
Metastases To Bone (cancer spreads to bone): 3 people, 6.38%
High Blood Pressure: 2 people, 4.26%
Neoplasm Malignant (cancer tumour): 1 person, 2.13%
High Blood Cholesterol: 1 person, 2.13%
Gastric Cancer (stomach cancer): 1 person, 2.13%
Depression: 1 person, 2.13%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 1 person, 2.13%
Breast Cancer Stage Iv: 1 person, 2.13%

* Approximation only. Some reports may have incomplete information.

Do you take Xeloda and have Muscle function loss?

- Check whether Muscle function loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xeloda:

Xeloda (46,649 reports)

Browse all side effects of Xeloda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Muscle function loss:

Muscle function loss (1,000 drugs)

Browse all the conditions that are associated with Muscle function loss:

Muscle function loss (1,520 conditions)

Related publications that referenced our studies

Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .
Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on capecitabine (the active ingredients of Xeloda) and Xeloda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.